Completed PHASE2 INTERVENTIONAL 2-arm NCT01658696

Efficacy of Candidate Malaria Vaccines in Senegalese Adults

Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection

Sponsor: European and Developing Countries Clinical Trials Partnership (EDCTP)

Conditions Malaria

Interventions ChAd63 ME-TRAP and MVA ME-TRAP Rabies vaccine

Updated 5 times since 2017 Last updated: Dec 11, 2013 Started: Aug 31, 2012 Primary completion: Feb 28, 2013 Completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01658696, this PHASE2 trial focuses on Malaria and remains completed. Sponsored by European and Developing Countries Clinical Trials Partnership (EDCTP), it has been updated 5 times since 2012, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European and Developing Countries Clinical Trials Partnership (EDCTP)
University of Oxford

Data source: University of Oxford

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dakar, Senegal